Tellgen Corporation (300642.SZ) researches, develops, manufactures and distributes in vitro diagnostic (IVD) products with a focus on tumor markers, molecular diagnostics and related testing solutions in China and internationally; headquartered in Shanghai, China, the company was founded in 2003 and listed on the Shenzhen Stock Exchange in 2017. Core offerings encompass tumor marker detection reagents including AFP, CEA, CA125, CA242, SCCA and multi-panel combinations such as the 12-item tumor marker panel, male nine/female eight tumor marker panels, lung cancer three- and five-item panels; HPV nucleic acid detection kits covering HPV27, HPV5+9 (targeting Chinese epidemiology with 16/18/58/52/33 subtypes), HPV2+12; reproductive health products like Y chromosome microdeletion (Y6) test kits compliant with EAA/EMQN guidelines; autoimmune, cardiovascular and inflammation markers; biochemistry kits; DNA methylation tests such as SHOX2/RASSF1A for lung cancer and Septin9 for colorectal cancer; infectious disease detection including COVID-19 molecular tests, Zika/Dengue/Chikungunya (approved in Thailand); PGI/PGII and G17 gastric cancer screening kits; diagnostic instruments and assembly lines like TESMI i100/i200 chemiluminescence immunoassay analyzers, TESMI F4000, NuaBox multiplex PCR systems, ImmunDuo modular automation, Hitachi-compatible流水线, rapid PCR cyclers; and quality control products like multi-tumor marker controls. Platforms include immunofluorescence, chemiluminescence immunoassay, multiplex fluorescent PCR, mass spectrometry and xMAP-based Tellgenplex technology, serving clinical diagnostics, physical exams and precision oncology from screening to prognosis. Recent developments feature the completed acquisition of a 72.9% stake in Wuhan HealthCare Biotechnology Co., Ltd. (HealthCare BIO) for RMB 291 million in August 2025, integrating its FastProbe rapid FISH probes for hematologic malignancies, solid tumors and companion diagnostics to form a full-chain Flow Fluorescence + PCR + FISH oncology strategy with international sales in over 40 countries; a strategic investment in CytoCares (Shanghai) Inc. in October 2025 to build a diagnosis-plus-therapy ecosystem for autoimmune diseases; a RMB 68 million investment in Huihe Bio for its CC312 dry eye pipeline; share repurchases totaling 0.45% of shares from August to September 2025; and subsidiary Wuhan Kanglu Biotechnology's medical device registration acceptance by the National Medical Products Administration in November 2025.